MCFD2

Across TCGA pan-cancer cohorts, MCFD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MCFD2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MCFD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCFD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, COAD, and CCRCC are the cancer types where MCFD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.823	1.000	.002	62	view →
COAD	DFS	Median	IV	0.493	0.944	.031	18	view →
CCRCC	OS	Tertile	IV	0.216	1.000	.014	15	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
GBM	OS	Quartile	All	0.733	0.884	.006	4	view →
HNSC	DFS	Tertile	III,IV	0.941	0.715	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MCFD2–LSCC (DFS)

Open the LSCC breakdown →